Thursday, February 28, 2013

• These 3 Stocks Fell Like a House of Cardsat Motley Fool (Thu, Feb 28)

Tuesday, February 26, 2013

• Peregrine Announces Participation at Upcoming Investor ConferencesMarketwired (Tue, Feb 26)
• Avid Bioservices to Highlight Recent Successes in Reducing Manufacturing Costs and Novel Ways of Controlling Critical Process Parameters That Lead to Consistent Product Quality at IBC'S Biopharmaceutical Development and Production ConferencMarketwired (Tue, Feb 26)
• Peregrine Pharmaceuticals' Bavituximab: It's Time To Throw In The Towelat Seeking Alpha (Tue, Feb 26)

Thursday, February 21, 2013

• A Biotech Winner For 2013at Seeking Alpha (Thu, Feb 21)

Wednesday, February 20, 2013

• Update on Peregrine's BavituximabZacks (Wed, Feb 20)

Tuesday, February 19, 2013

• PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online (Tue, Feb 19)
• Peregrine Investors: Once Bitten, Twice Shyat Motley Fool (Tue, Feb 19)
• Largest option buying in equities so faroptionMONSTER (Tue, Feb 19)
• 2 of These 3 Stocks Look Like Damaged Goodsat Motley Fool (Tue, Feb 19)
• Peregrine Pharmaceuticals Updates Top-Line Data From Phase II Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung CancerMarketwired (Tue, Feb 19)

Thursday, February 14, 2013

• Data on Peregrine's BavituximabZacks (Thu, Feb 14)
• Peregrine's Epic Failure (Maybe)at Motley Fool (Thu, Feb 14)
• U.S. Food and Drug Administration Approved 30% More Drugs in 2012Marketwired (Thu, Feb 14)
• Today's Market News To Trade On: 5 Stocks Moving On Newsat Seeking Alpha (Thu, Feb 14)

Wednesday, February 13, 2013

• 4 Heathcare Stock Stories Necessary for Investor Wellnessat Wall St. Cheat Sheet (Wed, Feb 13)
• PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online (Wed, Feb 13)
• Can Peregrine Match Celgene? No.at Motley Fool (Wed, Feb 13)
• Peregrine Pharma Is Wasting Money On A Placebo Cancer Drugat TheStreet (Wed, Feb 13)
• Peregrine Pharmaceuticals Announces Results From Phase II Clinical Trial of Bavituximab in Stage IV Pancreatic CancerMarketwired (Wed, Feb 13)

Tuesday, February 12, 2013

• Priority FDA Review for Celgene DrugZacks (Tue, Feb 12)
• What’s Moving These Biotech Stocks?at Motley Fool (Tue, Feb 12)

Monday, February 11, 2013

• Gilead Closes YM Biosciences BuyoutZacks (Mon, Feb 11)

Thursday, February 7, 2013

• Protalix Exploring OptionsZacks (Thu, Feb 7)
• 50% Upside on this Biotechnology Stockat Motley Fool (Thu, Feb 7)

Add PPHM News to My Yahoo!